INTERCEPT-AD: A Gender Analysis of the Phase 1 Experience Among Trial Participants with Early Alzheimer’s Disease and Their Study Partners

sabirnetug IV (ACU193 IV) - Acumen Pharma

Kelly Johnston1; Carrie Presnall1; Elizabeth Merikle1; Stephanie Cline2; Robyn Moxon2; Todd Feaster2; Eric Siemers2

Jun 20, 2024